Hospital Universitario Nuestra Senora De Candelaria — Clinical Trial Site

42 Registered trials

20 Currently recruiting

Organisation

Hospital Universitario Nuestra Senora De Candelaria

Location

Santa Cruz De Tenerife, Spain

Identifier

ORG-100044396

Address

Carretera De Rosario 145, Resto, 38010, Spain

Departments

2083: Hematologia
3209: Hematologia
Alergology
Allergology
Allergy
Allergyc
Aparato Digestivo
Department of Obstetrics and Gynecology
Gastroenterología
Gastroenterology and Hepatology
General and Digestive System Surgery
Hematología
Hematology
Hematology and Hemotherapy
Hospital Universitario Nuestra Señora de la Candelaria
Medical Oncology
Neumología
Neurology
Oncology
Oncology Service
Pediatric oncology and hematology department
Respiratory medicine
Servicio de Anestesiología y Reanimación.
Servicio de Neumología

Clinical trials at this site (42)

Search interface

Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D… Ended

2024-518519-20-01 moderate/severe allergic rhinitis/rhinoconjunctivitis w 4 2025-04-10
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Ended

2023-506503-26-00 Polyneuropathy, Inflammatory Demyelinating, Chronic 5 2024-07-31
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Previously Untreated Chronic Lymphocytic Leukemia 5 2024-04-05
AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISE… Ended

2024-516732-97-00 multiple sclerosis (MS) 5 2022-11-28
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
"Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended

2024-513730-38-00 Resectable Non-small cell lung cancer 5 2021-01-13
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA… Ended

2023-507304-32-00 Chronic Obstructive Pulmonary Disease 6 2024-02-09
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended

2022-501901-10-00 Chronic Hepatitis D Infection 6 2023-02-06
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended

2024-519691-10-00 Septic Shock 6 2022-05-27
A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab… Ended

2023-505975-54-00 Multiple Sclerosis (MS) 5 2022-03-28
Asciminib treatment optimization in ≥ 3rd line CML-CP Ended

2024-511381-36-00 Chronic Myelogenous Leukemia in chronic phase (CML-CP) 5 2021-10-13
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended

2024-514611-98-00 PIK3CA mutated HER2+ advanced or relapsed breast cancer 5 2021-07-20
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13